Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03599713 · OUTCOME

First-dose Cmin of Retifanlimab

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) · Source last updated 2025-08-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
μg/mL
Interval / dispersion
Standard Deviation
Time frame
preinfusion, 10 minutes postinfusion (± 10 minutes), and 4 hours postinfusion (± 10 minutes) on Day 1 of Cycle 1

What was measured

Cmin was defined as the minimum observed plasma concentration over the dose interval.

Analysis population: PK Evaluable Population

Groups in this outcome

All Participants

Participants with recurrent, advanced locoregional disease or distant metastatic disease who did not receive any prior chemotherapy received retifanlimab 500 mg, administered by IV infusion over 60 minutes on Day 1 Q4W.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Participants102

Reported measurements

Source class 1
Values in μg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
All Participants20.57.23Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        7.23
        value
        20.5
denoms
  1. counts
    1. group Id
      OG000
      value
      102
    units
    Participants
description
Cmin was defined as the minimum observed plasma concentration over the dose interval.
dispersion Type
Standard Deviation
groups
  1. description
    Participants with recurrent, advanced locoregional disease or distant metastatic disease who did not receive any prior chemotherapy received retifanlimab 500 mg, administered by IV infusion over 60 minutes on Day 1 Q4W.
    id
    OG000
    title
    All Participants
param Type
MEAN
population Description
PK Evaluable Population
reporting Status
POSTED
time Frame
preinfusion, 10 minutes postinfusion (± 10 minutes), and 4 hours postinfusion (± 10 minutes) on Day 1 of Cycle 1
title
First-dose Cmin of Retifanlimab
type
SECONDARY
unit Of Measure
μg/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice